Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. | Read by QxMD (original) (raw)

Journal Article

Research Support, Non-U.S. Gov't

Wen-Hung Chung, Shuen-Iu Hung, Jui-Yung Yang, Shih-Chi Su, Shien-Ping Huang, Chun-Yu Wei, See-Wen Chin, Chien-Chun Chiou, Sung-Chao Chu, Hsin-Chun Ho, Chih-Hsun Yang, Chi-Fang Lu, Jer-Yuarn Wu, You-Di Liao, Yuan-Tsong Chen

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening adverse drug reactions characterized by massive epidermal necrosis, in which the specific danger signals involved remain unclear. Here we show that blister cells from skin lesions of SJS-TEN primarily consist of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, and both blister fluids and cells were cytotoxic. Gene expression profiling identified granulysin as the most highly expressed cytotoxic molecule, confirmed by quantitative PCR and immunohistochemistry. Granulysin concentrations in the blister fluids were two to four orders of magnitude higher than perforin, granzyme B or soluble Fas ligand concentrations, and depleting granulysin reduced the cytotoxicity. Granulysin in the blister fluids was a 15-kDa secretory form, and injection of it into mouse skin resulted in features mimicking SJS-TEN. Our findings demonstrate that secretory granulysin is a key molecule responsible for the disseminated keratinocyte death in SJS-TEN and highlight a mechanism for CTL- or NK cell--mediated cytotoxicity that does not require direct cellular contact.

We have located links that may give you full text access.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-

2024

by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our

terms of use

and

privacy policy.

Your Privacy Choices Toggle icon

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app